Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review.

CONTEXT Selective eligibility criteria of randomized controlled trials (RCTs) are vital to trial feasibility and internal validity. However, the exclusion of certain patient populations may lead to impaired generalizability of results. OBJECTIVE To determine the nature and extent of exclusion criteria among RCTs published in major medical journals and the contribution of exclusion criteria to the representation of certain patient populations. DATA SOURCES AND STUDY SELECTION The MEDLINE database was searched for RCTs published between 1994 and 2006 in certain general medical journals with a high impact factor. Of 4827 articles, 283 were selected using a series technique. DATA EXTRACTION Trial characteristics and the details regarding exclusions were extracted independently. All exclusion criteria were graded independently and in duplicate as either strongly justified, potentially justified, or poorly justified according to previously developed and pilot-tested guidelines. DATA SYNTHESIS Common medical conditions formed the basis for exclusion in 81.3% of trials. Patients were excluded due to age in 72.1% of all trials (60.1% in pediatric populations and 38.5% in older adults). Individuals receiving commonly prescribed medications were excluded in 54.1% of trials. Conditions related to female sex were grounds for exclusion in 39.2% of trials. Of all exclusion criteria, only 47.2% were graded as strongly justified in the context of the specific RCT. Exclusion criteria were not reported in 12.0% of trials. Multivariable analyses revealed independent associations between the total number of exclusion criteria and drug intervention trials (risk ratio, 1.35; 95% confidence interval, 1.11-1.65; P = .003) and between the total number of exclusion criteria and multicenter trials (risk ratio, 1.26; 95% confidence interval, 1.06-1.52; P = .009). Industry-sponsored trials were more likely to exclude individuals due to concomitant medication use, medical comorbidities, and age. Drug intervention trials were more likely to exclude individuals due to concomitant medication use, medical comorbidities, female sex, and socioeconomic status. Among such trials, justification for exclusions related to concomitant medication use and comorbidities were more likely to be poorly justified. CONCLUSIONS The RCTs published in major medical journals do not always clearly report exclusion criteria. Women, children, the elderly, and those with common medical conditions are frequently excluded from RCTs. Trials with multiple centers and those involving drug interventions are most likely to have extensive exclusions. Such exclusions may impair the generalizability of RCT results. These findings highlight a need for careful consideration and transparent reporting and justification of exclusion criteria in clinical trials.

[1]  Robert M Califf,et al.  Peer-reviewed publication of clinical trials completed for pediatric exclusivity. , 2006, JAMA.

[2]  P. Rothwell,et al.  External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.

[3]  Phyllis N Butow,et al.  Clinical trials in children , 2004, The Lancet.

[4]  A. Laupacis,et al.  Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study , 2004 .

[5]  D. Juurlink,et al.  Heart failure/transplant: abstractsCyclo-oxy genase-2 inhibitors versus nonselective, nonsteroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: A population-based cohort study☆ , 2004 .

[6]  A. Laupacis,et al.  Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study , 2004, The Lancet.

[7]  M. Rieder,et al.  The trials and tribulations of doing drug research in children. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[8]  H. Krumholz,et al.  Race, ethnic group, and clinical research , 2003, BMJ : British Medical Journal.

[9]  J. Shaw,et al.  Rate limiting factors in recruitment of patients to clinical trials in cancer research: descriptive study , 2003, BMJ : British Medical Journal.

[10]  Harlan M Krumholz,et al.  Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. , 2003, American heart journal.

[11]  T. Pincus,et al.  Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission. , 2003, The Journal of rheumatology.

[12]  Stephen B. Johnson,et al.  Central challenges facing the national clinical research enterprise. , 2003, JAMA.

[13]  M. Egger,et al.  Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990 to 2001 , 2003, Heart.

[14]  Sigal Kaplan,et al.  Reported adverse drug events in infants and children under 2 years of age. , 2002, Pediatrics.

[15]  R. Steinbrook Testing medications in children. , 2002, The New England journal of medicine.

[16]  A. Hart,et al.  Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS , 2002, British Journal of Cancer.

[17]  Harlan M Krumholz,et al.  Representation of the elderly, women, and minorities in heart failure clinical trials. , 2002, Archives of internal medicine.

[18]  S. Fosså,et al.  Selection of Patients may Limit the Generalizability of Results from Cancer Trials , 2002, Acta oncologica.

[19]  Douglas G. Altman,et al.  Systematic Reviews in Health Care: Meta-Analysis in Context: Second Edition , 2008 .

[20]  K. Alexander,et al.  Representation of elderly persons and women in published randomized trials of acute coronary syndromes. , 2001, JAMA.

[21]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Annals of internal medicine.

[22]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[23]  G. Guyatt,et al.  Users' Guides to the Medical Literature: XXV. Evidence-based medicine: principles for applying the Users' Guides to patient care. Evidence-Based Medicine Working Group. , 2000, JAMA.

[24]  David J Harris,et al.  Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. , 2000, The New England journal of medicine.

[25]  G. Mensah,et al.  Using Angiotensin Converting Enzyme Inhibitors in African-American Hypertensives: A New Approach to Treating Hypertension and Preventing Target-Organ Damage , 2000, Current medical research and opinion.

[26]  M. Egger,et al.  The hazards of scoring the quality of clinical trials for meta-analysis. , 1999, JAMA.

[27]  J. Wilson,et al.  An update on the therapeutic orphan. , 1999, Pediatrics.

[28]  J. Blumer Off-label uses of drugs in children. , 1999, Pediatrics.

[29]  G H Guyatt,et al.  Users' guides to the medical literature: XVI. How to use a treatment recommendation. Evidence-Based Medicine Working Group and the Cochrane Applicability Methods Working Group. , 1999, JAMA.

[30]  C Bain,et al.  Threats to Applicability of Randomised Trials: Exclusions and Selective Participation , 1999, Journal of health services research & policy.

[31]  B. Schmidt,et al.  Do sick newborn infants benefit from participation in a randomized clinical trial , 1999 .

[32]  Hall Wd Representation of blacks, women, and the very elderly (aged > or = 80) in 28 major randomized clinical trials. , 1999 .

[33]  C Weijer,et al.  A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group. , 1998, Journal of clinical epidemiology.

[34]  L. Schneider,et al.  Eligibility of Alzheimer's Disease Clinic Patients for Clinical Trials , 1997, Journal of the American Geriatrics Society.

[35]  R. Gelber,et al.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.

[36]  E. Mansour,et al.  Barriers to clinical trials: Part III: Knowledge and attitudes of health care providers , 1994, Cancer.

[37]  W S Schain,et al.  Barriers to clinical trials: Part II: Knowledge and attitudes of potential participants , 1994 .

[38]  Gordon H. Guyatt,et al.  Users' Guides to the Medical Literature: II. How to Use an Article About Therapy or Prevention B. What Were the Results and Will They Help Me in Caring for My Patients? , 1994 .

[39]  G H Guyatt,et al.  Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. , 1994, JAMA.

[40]  G H Guyatt,et al.  USERS' GUIDES TO THE MEDICAL LITERATURE. II: HOW TO USE AN ARTICLE ABOUT THERAPY OR PREVENTION A. ARE THE RESULTS OF THE STUDY VALID ? , 1993 .

[41]  G. Greenberg,et al.  Drugs in Pregnancy and Lactation , 1990 .

[42]  P. Douglas Gender, cardiology, and optimal medical care. , 1986, Circulation.

[43]  E Garfield,et al.  Which medical journals have the greatest impact? , 1986, Annals of internal medicine.

[44]  S. Davis,et al.  Participants in prospective, randomized clinical trials for resected non‐small cell lung cancer have improved survival compared with nonparticipants in such trials , 1985, Cancer.

[45]  F. Harrell,et al.  Regression models for prognostic prediction: advantages, problems, and suggested solutions. , 1985, Cancer treatment reports.

[46]  C L Soskolne,et al.  Physicians' reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer. , 1984, The New England journal of medicine.

[47]  E. Lusk,et al.  Attitudes toward clinical trials among patients and the public. , 1982, JAMA.